| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8236769 | International Journal of Radiation Oncology*Biology*Physics | 2009 | 6 Pages |
Abstract
In summary, capecitabine 825 mg mâ1 twice a day (Days 1-33) and weekly oxaliplatin 40 mg mâ1 was safe and tolerable in combination with intensity-modulated radiotherapy. Furthermore, four cycles of XelOx could be applied before and after chemoradiotherapy in two thirds of the patients.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Ralf-Dieter M.D., Frederik M.D., Nadine M.D., Sabine M.D., Melanie M.D., Wilko M.D., Matthias M.D., Frank M.D., Markus M.D., Stefan M.D., Andreas M.D.,